STOCK TITAN

Humanigen Inc - HGEN STOCK NEWS

Welcome to our dedicated news page for Humanigen (Ticker: HGEN), a resource for investors and traders seeking the latest updates and insights on Humanigen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Humanigen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Humanigen's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.53%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
clinical trial
Humanigen Inc

Nasdaq:HGEN

HGEN Rankings

HGEN Stock Data

23.82k
110.48M
10.35%
0.49%
3.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Burlingame

About HGEN

kalobios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. our mission is to improve the lives of cancer patients with innovative, humaneered®, monoclonal antibodies. kalobios' humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products. using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. our pipeline is comprised of humaneered® antibodies. these antibodies are being investigated in clinical development programs focused on treating cancer: kb004 (anti-epha3) humaneered® mab to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s phase 2 expansion portion of its phase 1/2 clinical trial in hematologic malignancies; and kb003 (anti-gm-csf) humaneered® mab that kal